Revance Therapeutics Inc (OQ:RVNC)

Apr 12, 2024 08:00 am ET
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced two poster presentations on DAXXIFY® for the treatment of cervical dystonia at the annual meeting of American Academy of Neurology (AAN), taking place April 13-18, 2024, in Denver, Colorado.
Mar 27, 2024 04:05 pm ET
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units (“RSUs”) to 29 employees. The RSUs vest over four years, with 25% of the underlying shares vesting on each of the four anniversaries of the applicable vesting commencement date, subject to the new empl
Mar 04, 2024 09:25 am ET
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $6.25 per share. The gross proceeds from the public offering are expected to be $100.0 million, before deducting underwriting discounts and commissions and other offering expenses. The public offering is expected to close on or about March 6, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proc
Mar 04, 2024 06:37 am ET
Revance Announces Proposed Public Offering of Common Stock
Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced a proposed underwritten public offering of $100 million of its common stock. In addition, the Company expects to grant the underwriter a 30-day option to purchase additional shares in an amount not to exceed 15% of the number of shares of common stock offered in the public offering. The Company intends to use the net proceeds from the offering to advance the commercial growth of its aesthetics portfolio, including DAXXIFY® and the RHA® Collection of dermal fillers, support the launch of DAXXIFY® into the the
Feb 28, 2024 04:05 pm ET
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
Feb 21, 2024 08:01 am ET
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provi
Feb 21, 2024 08:00 am ET
Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences.
Feb 02, 2024 08:00 am ET
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
Revance Therapeutics, Inc. (RVNC) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J0589) for DAXXIFY®, indicated for the treatment of cervical dystonia in adults. J-Codes are product-specific reimbursement codes used by commercial insurance plans, Medicare, and other government
Feb 01, 2024 08:00 am ET
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference, taking place February 7-8, 2024, in New York, New York. Chief Executive Officer, Mark J. Foley, is scheduled to participate in a fireside chat on Thu
Jan 08, 2024 08:00 am ET
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
Revance Therapeutics, Inc. (NASDAQ:RVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook. A supplemental presentation can also be found on the company’s
Nov 08, 2023 04:06 pm ET
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (RVNC), today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
Nov 08, 2023 04:05 pm ET
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced the appointment of Erica Jordan, Senior Vice President of Commercial to Chief Commercial Officer (CCO), Aesthetics. As CCO, Erica will have global responsibility for all aesthetics commercial activity including commercial strategy, sales and marketing, branding, loyalty and engagement.
Nov 06, 2023 08:00 am ET
Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the following investor conferences.
Nov 05, 2023 01:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC
Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Nov 03, 2023 06:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC
NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Nov 01, 2023 08:00 am ET
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
Revance Therapeutics, Inc. (RVNC) today announced that the company will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate updat
Oct 27, 2023 03:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC
Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Oct 26, 2023 08:00 am ET
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
TIME® has unveiled its annual Best Inventions list, which features 200 of the year’s best innovations that are making the world better, smarter, and more enjoyable.
Oct 25, 2023 06:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC
NEW YORK, Oct. 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Oct 19, 2023 04:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC
Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Oct 17, 2023 09:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Sep 29, 2023 03:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC
NEW YORK, Sept. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Sep 25, 2023 04:34 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Revance Therapeutics, Inc. - RVNC
Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Sep 19, 2023 09:00 am ET
Revance Provides Corporate Update at Investor Day
Revance Therapeutics, Inc. (RVNC) announced that the company is hosting its Investor Day today, September 19, 2023, from 9:30 am ET to 12:00 pm ET.
Aug 22, 2023 08:00 am ET
Revance to Host Investor Day on September 19, 2023
Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the company will host an Investor Day on September 19, 2023, from 9:30 AM ET to 1:00 PM ET.
Aug 14, 2023 08:00 am ET
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved the first therapeutic indication for DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults.7 DAXXIFY®, powered by Peptide Exchange Technology™, was previously approved by the FDA for the temporary improvement of glabellar lines (frown lines) in adults in September 2022 and is the first true innovation in neuromodulator product formulation in more than 30 years.8-11
Aug 08, 2023 04:05 pm ET
Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (RVNC), today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
Aug 01, 2023 08:00 am ET
Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Revance Therapeutics, Inc. (RVNC), today announced that the company will release second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
May 23, 2023 04:05 pm ET
Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences.
May 09, 2023 04:05 pm ET
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (RVNC), today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
May 02, 2023 08:00 am ET
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
Apr 05, 2023 08:00 am ET
Revance to Participate in the Needham 22nd Annual Healthcare Conference
Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced that the company will participate in the 22nd Annual Needham Virtual Healthcare Conference, taking place April 17 – 20, 2023. Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday, April 18, at 12:45 P.M. ET.
Mar 30, 2023 08:00 am ET
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
Revance Therapeutics, Inc. (RVNC), today announced the release of its 2022 ESG Report, detailing the company’s progress towards its ESG priorities of innovation and access, workplace culture and strong corporate governance. The report was guided by the Sustainability Accounting Standards Board (SASB) framework.
Mar 07, 2023 08:00 am ET
Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the following investor conferences.
Feb 28, 2023 04:06 pm ET
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
Feb 28, 2023 04:05 pm ET
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
Revance Therapeutics, Inc. (RVNC), announced today the appointment of Dr. Vlad Coric, M.D., to its Board of Directors, effective March 1, 2023. Dr. Coric brings more than 22 years of drug development and executive leadership experience to Revance based on his time at the Yale School of Medicine, Bristol-Myers Squibb, and Biohaven, which was ac
Feb 27, 2023 08:00 am ET
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the 43rd Annual Cowen Healthcare Conference, taking place March 6-8, 2023, in Boston, Massachusetts.
Feb 23, 2023 08:00 am ET
Feb 21, 2023 04:05 pm ET
Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a
Jan 09, 2023 08:00 am ET
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
Revance Therapeutics, Inc. (RVNC) today provided an update on its early experience program for DAXXIFY® and its preliminary unaudited fourth quarter and full year 2022 financial results.
Jan 06, 2023 06:00 pm ET
Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults, a chronic and debilitating neurologic condition affecting the muscles of the neck.1 Revance was provided a Prescription Drug User Fee Act (PDUFA) date of August 19, 2023.
Nov 22, 2022 08:00 am ET
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 34th Annual Piper Sandler Healthcare Conference, taking place November 29-December 1, 2022, in New York City. Chief Executive Officer, Mark J. Foley, is scheduled to present on Tuesday, November 29, at 10:00AM ET.
Nov 17, 2022 07:00 am ET
Nanostics Announces New Member of Board of Directors
EDMONTON, AB, Nov. 17, 2022 /CNW/ - Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company.
Nov 17, 2022 07:00 am ET
Nanostics Announces New Member of Board of Directors
EDMONTON, AB, Nov. 17, 2022 /PRNewswire/ - Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company.
Nov 09, 2022 08:00 am ET
Revance to Participate in the Stifel 2022 Healthcare Conference
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Stifel 2022 Healthcare Conference, taking place November 15-16, 2022, in New York City. Chief Financial Officer, Tobin Schilke, is scheduled to present on Tuesday, November 15, at 3:00 p.m. ET.
Nov 08, 2022 04:05 pm ET
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (Nasdaq: RVNC), today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
Nov 04, 2022 08:00 am ET
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial-stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the publication of two peer-reviewed articles in the Aesthetic Surgery Journal, the official journal of The Aesthetic Society. The publications highlight the nuances of glabellar line (GL) injection technique and aim to improve patient outcomes, irrespective of the neuromodulator used. The first publication demonstrates the impact of subtle variations in glabellar line injection technique on eyebrow position, and the second propos
Nov 01, 2022 08:00 am ET
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release third quarter 2022 financial results on Tuesday, November 8, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.
Oct 20, 2022 08:00 am ET
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Revance Therapeutics, Inc. (Nasdaq: RVNC) a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for DAXXIFY™ for the treatment of cervical dystonia. Cervical dystonia is a painful and disabling chronic condition in which the neck muscles contract involuntarily, causing abnormal movements and awkward posture of the head and neck.1
Oct 17, 2022 08:00 am ET
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Medical Officer to lead clinical development, data science, medical affairs, scientific innovation, pharmacovigilance and regulatory affairs.
Oct 10, 2022 08:00 am ET
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced today it will present two video abstracts featuring DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection at the American Society for Dermatologic Surgery (ASDS) Annual Meeting taking place in Aurora, CO, from October 6-10, 2022.
Sep 21, 2022 08:00 am ET
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Guggenheim Nantucket Therapeutics Conference, taking place September 27 – 29, in Nantucket, MA.
Sep 19, 2022 08:00 am ET
Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the publication of two peer-reviewed articles in Aesthetic Surgery Journal, the official journal of The Aesthetic Society. The publications reported the impact of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection on brow position and frontalis muscle activity from a post-hoc analysis of patients in the Phase 2a forehead line (FHL) study and the SAKURA open-label safety (OLS) study as well as presenting the efficacy and safety of D
Sep 16, 2022 09:31 am ET
Thinking about buying stock in Revance Therapeutics, Uber Technologies, Roblox, Aditxt, or Roku?
NEW YORK, Sept. 16, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RVNC, UBER, RBLX, ADTX, and ROKU.
Sep 15, 2022 04:06 pm ET
Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkins
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced an oral presentation by Dr. Atul Patel, JUNIPER clinical investigator, will take place on Friday, September 16 at 2:30 pm GMT+ 2 at the International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Madrid, Spain. The presentation will include results from Revance’s JUNIPER Phase 2 clinical trial evaluating the efficacy and safety of three doses of DAXXIFY™ compared to placebo for adults with upper limb spasticity
Sep 15, 2022 04:05 pm ET
Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,200,000 additional shares, at a price to the public of $25.00 per share. All of the shares were offered by Revance. The aggregate gross proceeds from the public offering were $230.0 million, before deducting underwriting discou
Sep 12, 2022 09:32 pm ET
Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the pricing of an upsized underwritten public offering of 8,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $25.00 per share. All of the shares are being offered by Revance. The gross proceeds from the public offering are expected to be $200.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition
Sep 12, 2022 04:01 pm ET
Revance Announces Proposed Public Offering of Common Stock
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced a proposed underwritten public offering of $150 million of its common stock. In addition, Revance expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. The Company intends to use the net proceeds from the offering to fund the commercialization of DAXXIFY™, the RHA® Collection of dermal fillers and OPUL®, and for working
Sep 08, 2022 08:41 am ET
Thinking about buying stock in Amylyx Pharmaceuticals, Asana, Revance Therapeutics, Ardelyx, or GameStop?
NEW YORK, Sept. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMLX, ASAN, RVNC, ARDX, and GME.
Sep 08, 2022 07:00 am ET
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults.1 DAXXIFY™ is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum albumin and animal-based components.1-2,7-11 Most importantly, DAXXIFY™ has the abili
Aug 09, 2022 04:05 pm ET
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
Aug 02, 2022 04:05 pm ET
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.
Jul 27, 2022 08:00 am ET
Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the presentation of six abstracts to be presented at the 2022 TOXINS International Conference on July 27-30, 2022 in New Orleans, Louisiana.
May 23, 2022 08:00 am ET
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the William Blair 42nd Annual Growth Stock Conference, taking place June 6-9, in Chicago. Chief Executive Officer, Mark Foley, is scheduled to present on Monday, June 6, at 2:00 p.m. CT / 3:00 p.m. ET.
May 10, 2022 04:05 pm ET
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
May 03, 2022 08:00 am ET
Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release first quarter financial results on Tuesday, May 10, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.
Apr 21, 2022 04:05 pm ET
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.
Apr 13, 2022 03:29 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of Alfi, Inc. (NASDAQCM: ALF), Berkeley Lights, Inc. (NASDAQGS: BLI), Playtika Holding Corp. (NASDAQGS: PLTK), and Revance Therapeutics, Inc. (NASDAQGM
Alfi, Inc. (NASDAQCM: ALF) Lifshitz Law PLLC announces that a class action complaint has been filed against ALF alleging that the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (i) ALF...
Mar 28, 2022 08:00 am ET
Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced they will give one oral presentation and present one poster at the 2022 American Academy of Neurology Annual Meeting, taking place on April 2-7, 2022 in Seattle, Washington.
Mar 21, 2022 08:00 am ET
Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the closing of a $300 million note purchase agreement with funds managed by Athyrium Capital Management, LP, a leading healthcare-focused investment firm.
Mar 08, 2022 08:00 am ET
Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines in response to the Complete Response Letter (CRL) issued by the FDA in October 2021.
Mar 02, 2022 08:00 am ET
Revance to Participate in the Cowen 42nd Annual Health Care Conference
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference, a fully virtual management access conference, taking place March 7-9.
Feb 28, 2022 04:05 pm ET
Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
Feb 22, 2022 08:00 am ET
Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release fourth quarter and full year 2021 financial results on Monday, February 28, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.
Feb 08, 2022 04:00 pm ET
FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – RVNC
Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) and certain of its officers.   The class action, filed in the United States District Court for the...
Feb 08, 2022 05:00 am ET
RVNC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline TODAY in the Class Action Filed on Behalf of Revance Therapeutics, Inc. Shareholders
NEW YORK, Feb. 8, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC) alleging that the Company violated federal securities laws.
Feb 07, 2022 09:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Revance, Paysafe, Organogenesis, and Cloopen Group and Encourages Investors to Contact
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Revance Therapeutics, Inc. (NASDAQ: RVNC), Paysafe Limited (NYSE: PSFE),...
Feb 07, 2022 09:09 am ET
Final Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc. (RVNC)
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Revance Therapeutics, Inc....
Feb 07, 2022 05:00 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Revance Investors of a Lead Plaintiff Deadline of February 8, 2022
NEW YORK, Feb. 7, 2022 /PRNewswire/ -- Attention Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC) shareholders:
Feb 05, 2022 06:10 pm ET
TUESDAY DEADLINE: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RVNC
Robbins Geller Rudman & Dowd LLP announces that purchasers of Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (“Class Period”) have until this upcoming Tuesday, February 8, 2022, to seek appointment as lead plaintiff
Feb 05, 2022 09:54 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Revance Therapeutics (RVNC) Investors to Lead Plaintiff Opportunity in Securities Fraud Action
Hagens Berman urges Revance Therapeutics, Inc. (NASDAQ: RVNC) investors to with significant losses to submit your losses now. Class Period: Nov. 25, 2019 – Oct. 11, 2021Lead Plaintiff Deadline: Feb. 8, 2022Visit:...
Feb 04, 2022 09:00 pm ET
REVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Revance securities between November 25, 2019 and October 11, 2021, both dates included, (the “Class Period”). Investors have until February 8, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Feb 04, 2022 09:00 pm ET
REVANCE THERAPEUTICS 96 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against
NEW ORLEANS, Feb. 4, 2022 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until February 8, 2022 to file lead plaintiff applications in a securities class action lawsuit against Revance Therapeutics, Inc. (NasdaqGM: RVNC), if they purchased the Company's shares between November 25, 2019 and October 11, 2021, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.
Feb 04, 2022 05:02 pm ET
Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Revance Therapeutics, Inc. (RVNC) That a Securities Fraud Class Action Lawsuit Has Been Filed On Their Behalf
RADNOR, Pa., Feb. 4, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC). The action charges Revance with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a result of Revance's materially misleading statements to the public, Revance investors have suffered significant losses.
Feb 04, 2022 03:34 pm ET
RVNC Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Revance Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: February 8, 2022
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) and certain of its officers, on behalf of...
Feb 04, 2022 02:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC
NEW YORK, Feb. 4, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) and certain of its officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-09585, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between November 25, 2019 and October 11, 2021, both dates inclusive (the "Class Period"), seeking to recover
Feb 04, 2022 12:30 pm ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC)
The Law Offices of Frank R. Cruz reminds investors of the upcoming February 8, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:
Feb 03, 2022 12:00 pm ET
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Feb. 3, 2022 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).
Feb 02, 2022 11:57 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BLI, RAAS, RVNC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Berkeley Lights, Inc. (BLI)Class Period: 7/17/2020 - 9/14/2021Lead Plaintiff Motion Deadline: February...
Feb 02, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Revance, Shattuck Labs, and Standard Lithium and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Revance Therapeutics, Inc. (NASDAQ: RVNC), Shattuck Labs, Inc. (NASDAQ: STTK),...
Feb 02, 2022 03:34 pm ET
RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Feb. 2, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.
Feb 02, 2022 03:15 pm ET
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important February 8 Deadline in Securities Class Action – RVNC
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between November 25, 2019 and October 11, 2021, inclusive (the “Class Period”), of the important February...
Feb 01, 2022 10:25 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BLI, RAAS and RVNC
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Berkeley Lights, Inc. (BLI)Class Period: July 17, 2020 and September 14, 2021Lead Plaintiff Motion Deadline:...
Feb 01, 2022 02:05 pm ET
RVNC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 8, 2022 in the Class Action Filed on Behalf of Revance Therapeutics, Inc. Limited Shareholders
NEW YORK, Feb. 1, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC) alleging that the Company violated federal securities laws.
Feb 01, 2022 02:00 pm ET
DEADLINE ALERT for PSFE, BFT, RVNC, RAAS, and ORGO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 01, 2022 12:03 am ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS HOOD, MARA, RAAS, RVNC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Cloopen Group Holding Limited (RAAS)Class Period:...
Jan 31, 2022 06:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – RVNC
Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) and certain of its officers.   The class action, filed in the United States District Court for the...
Jan 31, 2022 03:24 pm ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Revance Investors of a Lead Plaintiff Deadline of February 8, 2022
NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Attention Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC) shareholders:
Jan 31, 2022 01:26 pm ET
RVNC 8-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Pendin
Hagens Berman urges Revance Therapeutics, Inc. (NASDAQ: RVNC) investors to with significant losses to submit your losses now. Class Period: Nov. 25, 2019 – Oct. 11, 2021Lead Plaintiff Deadline: Feb. 8, 2022Visit:...
Jan 29, 2022 09:01 pm ET
SECURITIES CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds RVNC Investors of Upcoming Deadline and Urges Investors with Substantial Losses to Contact the Firm
RADNOR, Pa., Jan. 29, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC). The action charges Revance with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a result of Revance's materially misleading statements to the public, Revance investors have suffered significant losses.
Jan 28, 2022 10:00 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BLI, RAAS, RVNC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Berkeley Lights, Inc. (BLI)Class Period: 7/17/2020 - 9/14/2021Lead Plaintiff Motion Deadline: February...
Jan 28, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sleep Number, Revance, Paysafe, and Organogenesis and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Sleep Number Corporation (NASDAQ: SNBR), Revance Therapeutics, Inc. (NASDAQ:...
Jan 28, 2022 06:21 pm ET
Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Revance Therapeutics, Inc. (RVNC) Investors and Encourages Investors to Contact the Firm Before
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Revance Therapeutics, Inc. (“Revance” or the...
Jan 28, 2022 03:31 pm ET
RVNC Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Revance Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: February 8, 2022
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) and certain of its officers, on behalf of...
Jan 28, 2022 01:10 pm ET
RVNC SHAREHOLDER ALERT: Jakubowitz Law Reminds Revance Shareholders of a Lead Plaintiff Deadline of February 8, 2022
NEW YORK, Jan. 28, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).
Jan 27, 2022 06:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-09585, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between November 25, 2019 and October 11, 2021, both dates inclusive (the "Class Period"), seeking to recover
Jan 27, 2022 12:58 pm ET
Jan 27, 2022 11:30 am ET
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES, Jan. 27, 2022 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).
Jan 27, 2022 12:33 am ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS HOOD, MARA, RAAS, RVNC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Cloopen Group Holding Limited (RAAS)Class Period:...
Jan 26, 2022 09:20 pm ET
Final Deadline Approaching on LP Deadline Date: Kessler Topaz Meltzer & Check, LLP Reminds Revance Therapeutics, Inc. Investors of Class Action Lawsuit Deadline
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Revance Therapeutics, Inc....
Jan 26, 2022 03:42 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - (RVNC)
NEW YORK, Jan. 26, 2022 /PRNewswire/ -- The Gross Law Firm, securities class action litigators, issues the following notice to shareholders of Revance Therapeutics, Inc.:
Jan 26, 2022 12:04 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BLI, RAAS and RVNC
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Berkeley Lights, Inc. (BLI)Class Period: July 17, 2020 and September 14, 2021Lead Plaintiff Motion Deadline:...
Jan 25, 2022 01:00 pm ET
DEADLINE ALERT for BLI, PSFE, RVNC, RAAS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 25, 2022 12:09 am ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BLI, RAAS, RVNC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Berkeley Lights, Inc. (BLI)Class Period: 7/17/2020 - 9/14/2021Lead Plaintiff Motion Deadline: February...
Jan 24, 2022 11:15 am ET
DEADLINE ALERT for PSFE, BFT, RVNC, RAAS, and ORGO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 24, 2022 09:37 am ET
RVNC DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Pending
Hagens Berman urges Revance Therapeutics, Inc. (NASDAQ: RVNC) investors to with significant losses to submit your losses now. Class Period: Nov. 25, 2019 – Oct. 11, 2021Lead Plaintiff Deadline: Feb. 8, 2022Visit:...
Jan 23, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Revance Therapeutics, Cloopen Group, Exicure, and Sleep Number and Encourages Investors to Contact the
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Revance Therapeutics, Inc. (NASDAQ: RVNC), Cloopen Group Holding Limited (NYSE:...
Jan 23, 2022 11:30 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – RVNC
Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) and certain of its officers. The class action, filed in the United States District Court for the...
Jan 22, 2022 11:10 am ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important February 8 Deadline in Securities Class Action – RVNC
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between November 25, 2019 and October 11, 2021, inclusive (the “Class Period”), of the important February 8,...
Jan 21, 2022 09:43 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS HOOD, MARA, RAAS, RVNC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Cloopen Group Holding Limited (RAAS)Class Period:...
Jan 21, 2022 04:53 pm ET
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Revance Therapeutics, Inc. (RVNC) Investors and Encourages Investors to Contact
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:
Jan 21, 2022 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 8, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc....
Jan 20, 2022 04:55 pm ET
Jan 20, 2022 08:49 am ET
SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds RVNC Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf
RADNOR, Pa., Jan. 20, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC). The action charges Revance with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Revance's materially misleading statements to the public, Revance investors have suffered significant losses.
Jan 19, 2022 11:29 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BLI, RAAS, RVNC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Berkeley Lights, Inc. (BLI)Class Period: 7/17/2020 - 9/14/2021Lead Plaintiff Motion Deadline: February...
Jan 18, 2022 11:45 pm ET
DEADLINE ALERT for PSFE, BFT, RVNC, RAAS, and ORGO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 18, 2022 10:32 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BLI, RAAS and RVNC
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Berkeley Lights, Inc. (BLI)Class Period: July 17, 2020 and September 14, 2021Lead Plaintiff Motion Deadline:...
Jan 18, 2022 09:02 pm ET
Lost Money in Revance Therapeutics, Inc.?
A Revance Securities Class Action Lawsuit has been filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between November 25, 2019, and October 11, 2021 (the “Class Period”). Revance investors are encouraged to
Jan 18, 2022 05:39 pm ET
REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsu
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 8, 2022 to file lead plaintiff applications in a securities class action lawsuit against...
Jan 18, 2022 04:05 pm ET
Revance Receives Clarity on Path to Resubmission of the BLA for DaxibotulinumtoxinA for Injection Following Type A Meeting with FDA
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, announced today that it has received the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for DaxibotulinumtoxinA for Injection for glabellar lines. The Type A meeting was held on December 15, 2021.
Jan 18, 2022 02:11 pm ET
RVNC INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed
Hagens Berman urges Revance Therapeutics, Inc. (NASDAQ: RVNC) investors to with significant losses to submit your losses now. Class Period: Nov. 25, 2019 – Oct. 11, 2021Lead Plaintiff Deadline: Feb. 8, 2022Visit:...
Jan 18, 2022 10:45 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) Investors
LOS ANGELES, Jan. 18, 2022 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (the "Class Period"). Revance investors have until February 8, 2022 to file a lead plaintiff motion.
Jan 17, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Paysafe, Revance Therapeutics, and Cloopen Group and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Paysafe Limited (NYSE: PSFE), Revance Therapeutics, Inc. (NASDAQ: RVNC), and...
Jan 17, 2022 08:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC
NEW YORK, Jan. 17, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-09585, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between November 25, 2019 and October 11, 2021, both dates inclusive (the "Class Period"), seeking to recover
Jan 17, 2022 09:51 am ET
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc. (RVNC) on Their Behalf
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Revance Therapeutics, Inc. (“Revance”)...
Jan 16, 2022 10:09 am ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – RVNC
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between November 25, 2019 and October 11, 2021, inclusive (the “Class Period”), of the important February 8,...
Jan 15, 2022 09:31 am ET
(RVNC) News: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Revance Therapeutics Class Action Lawsuit
Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Revance Therapeutics, Inc. (“Revance Therapeutics” or the “Company”) (NASDAQ: RVNC) who purchased securities during the...
Jan 14, 2022 08:54 pm ET
REVANCE THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 8, 2022 to file lead plaintiff applications in a securities class action lawsuit against Revance Therapeutics, Inc. (NasdaqGM: RVNC), if they...
Jan 14, 2022 06:36 pm ET
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Revance Therapeutics, Inc. (RVNC) Investors and Encourages Investors to Contact
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Revance Therapeutics, Inc. (“Revance” or the...
Jan 14, 2022 01:30 pm ET
DEADLINE ALERT for BLI, PSFE, RVNC, RAAS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 13, 2022 09:57 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Revance Therapeutics, Inc. - RVNC
CEDARHURST, N.Y., Jan. 13, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Revance Therapeutics, Inc. (NasdaqGM: RVNC), if they purchased the Company's shares between November 25, 2019 and October 11, 2021, inclusive (the "Class Period"). Shareholders have until February 8, 2022 to file lead plaintiff applications in the securities class action lawsuit.
Jan 13, 2022 02:57 pm ET
RVNC DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Pending
Hagens Berman urges Revance Therapeutics, Inc. (NASDAQ: RVNC) investors to with significant losses to submit your losses now. Class Period: Nov. 25, 2019 – Oct. 11, 2021Lead Plaintiff Deadline: Feb. 8, 2022Visit:...
Jan 13, 2022 11:54 am ET
PSFE, RVNC & RAAS – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions and Lead Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jan 13, 2022 09:26 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – RVNC
Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) and certain of its officers.   The class action, filed in the United States District Court for the...
Jan 12, 2022 10:00 pm ET
REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsu
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 8, 2022 to file lead plaintiff applications in a securities class action lawsuit against...
Jan 12, 2022 08:07 pm ET
REVANCE THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC
NEW ORLEANS, Jan. 12, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 8, 2022 to file lead plaintiff applications in a securities class action lawsuit against Revance Therapeutics, Inc. (NasdaqGM: RVNC), if they purchased the Company's shares between November 25, 2019 and October 11, 2021, inclusive (the "Class Period").  This action is pending in the United States District Court for the Northern District of California.
Jan 12, 2022 05:11 pm ET
Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc.
RADNOR, Pa., Jan. 12, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC). The action charges Revance with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Revance's materially misleading statements to the public, Revance investors have suffered significant losses.
Jan 12, 2022 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 8, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc....
Jan 11, 2022 10:53 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Revance Therapeutics, Inc. - RVNC
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Revance Therapeutics, Inc. (NasdaqGM: RVNC), if they purchased the Company’s shares between November 25, 2019 and October 11, 2021, inclusive (the “Class...
Jan 11, 2022 08:51 pm ET
Lost Money in Revance Therapeutics, Inc.?
A Revance Securities Class Action Lawsuit has been filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between November 25, 2019, and October 11, 2021 (the “Class Period”). Investors who lost money in Revance
Jan 11, 2022 11:45 am ET
DEADLINE ALERT for PSFE, BFT, RVNC, RAAS, and ORGO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 10, 2022 11:37 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS LSPD, RAAS, RVNC, STNE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Lightspeed Commerce, Inc. (LSPD)Class Period: 9/11/2020 - 11/3/2021Lead Plaintiff Motion Deadline:...
Jan 10, 2022 12:33 pm ET
Jan 10, 2022 09:00 am ET
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Jan. 10, 2022 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).
Jan 09, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Organogenesis, Paysafe, Revance Therapeutics, and Cloopen Group and Encourages Investors to Contact the
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Organogenesis Holdings, Inc. (NASDAQ: ORGO), Paysafe Limited (NYSE: PSFE),...
Jan 09, 2022 03:13 pm ET
RVNC CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Revance Therapeutics, Inc. Shareholders of Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Revance Therapeutics, Inc. (“Revance”)...
Jan 08, 2022 01:10 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Revance Therapeutics (RVNC) Investors to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action
Hagens Berman urges Revance Therapeutics, Inc. (NASDAQ: RVNC) investors to with significant losses to submit your losses now. Class Period: Nov. 25, 2019 – Oct. 11, 2021Lead Plaintiff Deadline: Feb. 8, 2022Visit:...
Jan 08, 2022 10:45 am ET
ROSEN, A LONGSTANDING LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – RVNC
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between November 25, 2019 and October 11, 2021, inclusive (the “Class Period”), of the important February 8,...
Jan 07, 2022 10:38 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS HOOD, MARA, RAAS, RVNC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Cloopen Group Holding Limited (RAAS)Class Period:...
Jan 07, 2022 06:11 pm ET
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Revance Therapeutics, Inc. (RVNC) Investors and Encourages Investors to Contact
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:
Jan 07, 2022 08:00 am ET
Revance Provides Preliminary Fourth Quarter and Full Year 2021 Financial Results and a Corporate Update
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today provided preliminary fourth quarter and full year 2021 financial results and a corporate update.
Jan 06, 2022 05:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) and certain of its officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-09585, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between November 25, 2019 and October 11, 2021, both dates inclusive (the "Class Period"), seeking to recover
Jan 06, 2022 12:00 pm ET
DEADLINE ALERT for BLI, PSFE, RVNC, RAAS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 06, 2022 11:53 am ET
PSFE, RVNC & RAAS – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions and Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jan 06, 2022 01:10 am ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS LSPD, RAAS, RVNC, STNE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Lightspeed Commerce, Inc. (LSPD)Class Period: 9/11/2020 - 11/3/2021Lead Plaintiff Motion Deadline:...
Jan 05, 2022 07:19 pm ET
Lost Money in Revance Therapeutics, Inc.?
A Revance Securities Class Action Lawsuit has been filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between November 25, 2019, and October 11, 2021. Revance investors are encouraged to contact Gibbs Law Gro
Jan 05, 2022 05:25 pm ET
REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsu
NEW ORLEANS, Jan. 5, 2022 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 8, 2022 to file lead plaintiff applications in a securities class action lawsuit against Revance Therapeutics, Inc. (NasdaqGM: RVNC), if they purchased the Company's shares between November 25, 2019 and October 11, 2021, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.
Jan 05, 2022 11:15 am ET
DEADLINE ALERT for PSFE, BFT, RVNC, RAAS, and ORGO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 05, 2022 12:49 am ET
FILING DEADLINE -- Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CTXS, RAAS, RVNC and STNE
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Citrix Systems, Inc. (CTXS)Class Period: January 22, 2020 and October 6, 2021Lead Plaintiff Motion Deadline:...
Jan 04, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Paysafe, Revance, Cloopen Group, and Exicure and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Paysafe Limited (NYSE: PSFE), Revance Therapeutics, Inc. (NASDAQ: RVNC), Cloopen...
Jan 04, 2022 04:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – RVNC
Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) and certain of its officers.   The class action, filed in the United States District Court for the...
Jan 04, 2022 12:00 pm ET
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES, Jan. 4, 2022 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).
Jan 04, 2022 11:00 am ET
RVNC Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Revance Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Revance securities between November 25, 2019 and October 11, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Jan 04, 2022 08:05 am ET
REVANCE THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Revance Therapeutics, Inc. in the Unite
NEW YORK, Jan. 4, 2022 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a federal securities class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Revance securities between November 25, 2019 and October 11, 2021, both dates included, (the "Class Period").
Jan 03, 2022 10:26 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS HOOD, MARA, RAAS, RVNC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Cloopen Group Holding Limited (RAAS)Class Period:...
Jan 03, 2022 03:15 pm ET
RVNC INVESTOR NEWS: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – RV
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between November 25, 2019 and October 11, 2021, inclusive (the “Class Period”), of the important February 8,...
Jan 03, 2022 03:07 pm ET
Lead Plaintiff Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc.
RADNOR, Pa., Jan. 3, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC). The action charges Revance with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a result of Revance's materially misleading statements to the public, Revance investors have suffered significant losses.
Jan 03, 2022 02:30 pm ET
RVNC FRAUD ALERT: Hagens Berman Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending
Hagens Berman urges Revance Therapeutics, Inc. (NASDAQ: RVNC) investors to with significant losses to submit your losses now. Class Period: Nov. 25, 2019 – Oct. 11, 2021Lead Plaintiff Deadline: Feb. 8, 2022Visit:...
Jan 03, 2022 01:37 pm ET
Jan 01, 2022 04:17 pm ET
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc. (RVNC)
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Revance Therapeutics, Inc. (“Revance”)...
Dec 31, 2021 10:00 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS LSPD, RAAS, RVNC, STNE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Lightspeed Commerce, Inc. (LSPD)Class Period: 9/11/2020 - 11/3/2021Lead Plaintiff Motion Deadline:...
Dec 31, 2021 01:50 pm ET
UPCOMING DEADLINE ALERT: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, Dec. 31, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ: RVNC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 30, 2021 10:15 pm ET
ALERT: Revance Therapeutics, Inc. Investors with Significant Losses Have Opportunity to Lead Class Action Lawsuit - RVNC
SAN DIEGO, Dec. 30, 2021 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (the "Class Period") have until February 8, 2022, to seek appointment as lead plaintiff in Aramic LLC v. Revance Therapeutics, Inc., No. 21-cv-09585 (N.D. Cal.). Commenced on December 10, 2021 and assigned to Judge Edward J. Davila, the Revance Therapeutics class action lawsuit charges Revance Therapeutics along with certain of its top executives wi
Dec 30, 2021 09:00 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Revance Therapeutics, Inc. - RVNC
CEDARHURST, N.Y., Dec. 30. 2021 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Revance Therapeutics, Inc. (NasdaqGM: RVNC), if they purchased the Company's shares between November 25, 2019 and October 11, 2021, inclusive (the "Class Period"). Shareholders have until February 8, 2022 to file lead plaintiff applications in the securities class action lawsuit.
Dec 30, 2021 12:50 pm ET
DEADLINE ALERT for RVNC, RAAS, ORGO, and XCUR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 30, 2021 11:52 am ET
PSFE, RVNC & RAAS – Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Actions and Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Dec 29, 2021 11:26 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS HOOD, MARA, RAAS, RVNC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Cloopen Group Holding Limited (RAAS)Class...
Dec 29, 2021 10:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC
NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) and certain of its officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-09585, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between November 25, 2019 and October 11, 2021, both dates inclusive (the "Class Period"), seeking to recove
Dec 29, 2021 06:01 pm ET
REVANCE THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC
NEW ORLEANS, Dec. 29, 2021 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 8, 2022 to file lead plaintiff applications in a securities class action lawsuit against Revance Therapeutics, Inc. (NasdaqGM: RVNC), if they purchased the Company's shares between November 25, 2019 and October 11, 2021, inclusive (the "Class Period").  This action is pending in the United States District Court for the Northern District of California.
Dec 29, 2021 02:11 pm ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors With Substantial Losses to Contact the Firm
SAN DIEGO, Dec. 29, 2021 /PRNewswire/ -- Johnson Fistel, LLP, announces that class action lawsuits have commenced on behalf of shareholders of the publicly traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving as lead
Dec 29, 2021 10:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 8, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc....
Dec 28, 2021 11:34 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CTXS, RAAS, RVNC and STNE
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Citrix Systems, Inc. (CTXS)Class Period: January 22, 2020 and October 6, 2021Lead Plaintiff Motion Deadline:...
Dec 28, 2021 02:54 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important February 8 Deadline in Securities Class Action – RVNC
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between November 25, 2019 and October 11, 2021, inclusive (the “Class Period”), of the important February 8,...
Dec 28, 2021 01:00 pm ET
DEADLINE ALERT for BLI, PSFE, RVNC, RAAS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 28, 2021 09:57 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
Hagens Berman urges Revance Therapeutics, Inc. (NASDAQ: RVNC) investors to with significant losses to submit your losses now. Class Period: Nov. 25, 2019 – Oct. 11, 2021Lead Plaintiff Deadline: Feb. 8, 2022Visit:...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.